GlassScriptPhysician profile
Andy R Wilson
NPI 1023366887
$4,858.34
in general payments reported to CMS, 2019-2025
42 companies · $765 in 2025
The $765 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,490 · 2022: $925 · 2023: $1,026 · 2024: $652 · 2025: $765.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,443.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,443.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $818.65 | 2021-2025 | |
| Amgen INC. | $443.44 | 2021-2022 | |
| Pfizer INC. | $385.84 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $353.25 | 2021-2025 | Relistor |
| Boston Scientific Corporation | $301.71 | 2021-2025 | Bionic Navigator, Wavewriter Alpha Prime 16, General - Therapies |
| Almatica Pharma LLC | $274.06 | 2021-2023 | Gralise |
| Biohaven Pharmaceutical Holding Company LTD. | $202.16 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $182.57 | 2021 | |
| Tersera Therapeutics LLC | $173.58 | 2021-2025 | Prialt |
| Lilly USA, LLC | $160.95 | 2021-2023 | Emgality, Reyvow |
| Ibsa Pharma INC. | $122.26 | 2023-2025 | Tirosint, Licart, Tirosint |
| Indivior INC. | $105.93 | 2021-2024 | Sublocade |
| Biodelivery Sciences International, INC. | $103.24 | 2021 | |
| Idorsia Pharmaceuticals US INC | $95.25 | 2022-2025 | Quviviq, Quviviq |
| Orexo US, INC. | $92.74 | 2021-2025 | Zubsolv |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Virtus Pharmaceuticals LLC | $83.04 | 2021 | |
| Saluda Medical Americas, INC. | $82.94 | 2025 | Evoke |
| Redhill Biopharma INC. | $62.75 | 2021 | |
| Eisai INC. | $55.88 | 2021-2022 | |
| Valinor Pharma, LLC | $54.32 | 2024-2025 | Movantik |
| Abbott Laboratories | $53.58 | 2021-2023 | Proclaim |
| Arbor Pharmaceuticals, INC. | $53.38 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $51.00 | 2021 | |
| Forte Bio-Pharma LLC | $50.50 | 2024 | Prolate, Nalocet |
| Grt US Holding, INC. | $47.83 | 2021 | |
| Azurity Pharmaceuticals, INC. | $45.98 | 2023 | Horizant |
| Nalu Medical, INC. | $38.96 | 2021-2024 | Nalu Neurostimulation System |
| Nevro Corp. | $36.47 | 2023-2024 | Senza |
| Avanos Medical | $35.39 | 2024 | Standard Rf Disposables |
| Scilex Pharmaceuticals INC. | $34.67 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $31.22 | 2021 | |
| Alnylam Pharmaceuticals INC. | $27.55 | 2024 | Givlaari |
| Medtronic, INC. | $27.21 | 2023 | Intellis Adaptivestim |
| Lundbeck LLC | $25.37 | 2023 | Vyepti |
| Painteq LLC | $22.14 | 2024 | Painteq |
| Globus Medical, INC. | $20.77 | 2025 | Senza |
| Hikma Pharmaceuticals USA | $19.73 | 2022 | |
| Depuy Synthes Sales INC. | $18.85 | 2023 | Monovisc |
| Amneal Pharmaceuticals LLC | $18.00 | 2023 | Lyvispah |
| Si-Bone, INC. | $17.66 | 2025 | |
| Uswm, LLC | $14.60 | 2021 | |
| Upsher-Smith Laboratories LLC | $12.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andy Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.